The DeSci project CureX will use business revenue to repurchase and destroy CUX tokens

According to official news, CureX recently announced that it will use 20% of the sales revenue from its TRC-T treatment for malignant pleural sarcoma to repurchase and destroy CUX. In the first round of repurchases, CureX bought 100 SOLs and successfully destroyed 4,259,993 CUX tokens. This operation signifies that while promoting the application of its biotechnology products, CureX has further strengthened the value and market stability of CUX tokens. It is reported that the biotherapy technology TRC-T is now in use in hospitals in Bangkok, Thailand, and the first batch of patients have received this treatment. CureX promises to continue using a portion of its product income to repurchase and destroy CUX tokens in future. CureX will continue to be committed to developing advanced biotech products to solve more disease problems and bring about changes in global healthcare industry through innovative blockchain technology.